Comparing the clinical evolution of cystic fibrosis screened neonatally to that of cystic fibrosis diagnosed from clinical symptoms: a 10-year retrospective study in a French region (Brittany)
- PMID: 12687590
- DOI: 10.1002/ppul.10259
Comparing the clinical evolution of cystic fibrosis screened neonatally to that of cystic fibrosis diagnosed from clinical symptoms: a 10-year retrospective study in a French region (Brittany)
Abstract
Until the year 2000, systematic cystic fibrosis (CF) neonatal screening was only performed in a few regions of France. The Brittany region began in 1989, but not the neighboring region of Loire-Atlantique. The present study compares the clinical evolution of both affected populations 10 years after screening was started. Although the 77 screened and 36 nonscreened children were followed in different CF centers, they were included in similar care protocols. The clinical characteristics at diagnosis and their evolution over a 10-year period of all the children affected with CF and born between January 1, 1989 and December 31, 1998, excluding those with meconium ileus, were compared. There were no significant differences in sex ratio, gestational age, anthropometric data at birth, frequency of deltaF508 homozygotes, proportion of pancreatic-insufficient patients, and mean age between the two populations. Age at diagnosis was lower in the screened group (38 days vs. 472 days, P < 10(-7)), as was the delay in supplementation with pancreatic enzymes (1.7 months vs.15.9 months, P < 10(-7)). The proportion of children who were hospitalized at least once was higher among the nonscreened than the screened patients (86% vs. 49%, P < 10(-4)). Z-scores for weight and height were significantly better in the screened population, not only in the first years of life, but also at 5 years old for height and 8 years old for weight. The Shwachman and Brasfield scores were higher among the screened children during the whole period of follow-up. No significant differences in colonization by Pseudomonas aeruginosa nor in lung function were found. Given the homogeneity in the characteristics and the follow-up of both populations, the benefits in terms of nutrition and clinical well-being of neonatal screening appear to be clear, thus confirming the advantages of its general implementation.
Copyright 2003 Wiley-Liss, Inc.
Similar articles
-
Cystic fibrosis diagnosed after 2 months of age leads to worse outcomes and requires more therapy.Pediatrics. 2007 Jan;119(1):19-28. doi: 10.1542/peds.2006-1498. Pediatrics. 2007. PMID: 17200267
-
[Does neonatal screening of cystic fibrosis affect outcome? Comparative study of two cohorts in Britanny and Loire-Atlantique with follow-up after ten years].Arch Pediatr. 2000 Nov;7(11):1154-62. doi: 10.1016/s0929-693x(00)00124-x. Arch Pediatr. 2000. PMID: 11109941 French.
-
Neonatal screening for cystic fibrosis does not affect time to first infection with Pseudomonas aeruginosa.Pediatrics. 2006 Sep;118(3):888-95. doi: 10.1542/peds.2004-2599. Pediatrics. 2006. PMID: 16950978
-
Review of outcomes of neonatal screening for cystic fibrosis versus non-screening in Europe.J Pediatr. 2005 Sep;147(3 Suppl):S15-20. doi: 10.1016/j.jpeds.2005.08.009. J Pediatr. 2005. PMID: 16202775 Review.
-
Overview of published evidence on outcomes with early diagnosis from large US observational studies.J Pediatr. 2005 Sep;147(3 Suppl):S11-4. doi: 10.1016/j.jpeds.2005.08.010. J Pediatr. 2005. PMID: 16202774 Review.
Cited by
-
Is newborn screening for cystic fibrosis a basic human right?J Cyst Fibros. 2008 May;7(3):262-5. doi: 10.1016/j.jcf.2008.01.001. Epub 2008 Feb 11. J Cyst Fibros. 2008. PMID: 18262856 Free PMC article.
-
The Impact of Highly Effective CFTR Modulators on Growth and Nutrition Status.Nutrients. 2021 Aug 24;13(9):2907. doi: 10.3390/nu13092907. Nutrients. 2021. PMID: 34578785 Free PMC article. Review.
-
Nutritional Care in Children with Cystic Fibrosis.Nutrients. 2023 Jan 17;15(3):479. doi: 10.3390/nu15030479. Nutrients. 2023. PMID: 36771186 Free PMC article. Review.
-
Improved detection of cystic fibrosis by the California Newborn Screening Program for all races and ethnicities.Pediatr Pulmonol. 2024 Nov;59(11):2901-2909. doi: 10.1002/ppul.27155. Epub 2024 Jun 28. Pediatr Pulmonol. 2024. PMID: 38940324 Free PMC article.
-
Innovative assessment of inpatient and pulmonary drug costs for children with cystic fibrosis.Pediatr Pulmonol. 2016 Dec;51(12):1295-1303. doi: 10.1002/ppul.23554. Epub 2016 Oct 14. Pediatr Pulmonol. 2016. PMID: 27740724 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical